{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:33Z","timestamp":1790755653860,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1136\/ard.2005.048744","type":"journal-article","created":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T01:25:18Z","timestamp":1139880318000},"page":"1233-1236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients"],"prefix":"10.1016","volume":"65","author":[{"given":"P","family":"Efthimiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Kagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.048744_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1136\/ard.2005.048744_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0889-857X(02)00025-X","article-title":"Possible pathogenic mechanisms in inflammatory myopathies","volume":"28","author":"Lundberg","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard.2005.048744_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-510X(96)00280-8","article-title":"Expression of tumor necrosis factor-alpha in muscles of polymyositis","volume":"146","author":"Tateyama","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1136\/ard.2005.048744_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1523-1747.2002.01869.x","article-title":"Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis","volume":"119","author":"Werth","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2005.048744_bib5","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.1780371206","article-title":"Elevated serum levels of interleukin-1 receptor antagonist in polymyositis\/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response","volume":"37","author":"Gabay","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048744_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s100670070027","article-title":"Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis","volume":"19","author":"Shimizu","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2005.048744_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(95)00122-0","article-title":"Analysis of cytokine expression in muscle in inflammatory myopathies, duchenne dystrophy, and non-weak controls","volume":"63","author":"Lundberg","year":"1995","journal-title":"J Neuroimmunol"},{"key":"10.1136\/ard.2005.048744_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s004010051165","article-title":"Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis","volume":"99","author":"Kuru","year":"2000","journal-title":"Acta Neuropathol (Berlin)"},{"key":"10.1136\/ard.2005.048744_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00005072-199603000-00009","article-title":"Cytokine expression profile in idiopathic inflammatory myopathies","volume":"55","author":"Tews","year":"1996","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1136\/ard.2005.048744_bib10","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1136\/ard.2004.032359","article-title":"Contribution of TNFa and IL-1b to IL-6 production, NF-kB nuclear translocation and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors","volume":"64","author":"Chevrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.048744_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/rheumatology\/keh062","article-title":"Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1","volume":"43","author":"Sprott","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2005.048744_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1136\/ard.2005.048744_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000079547","article-title":"Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up","volume":"52","author":"Hengstman","year":"2004","journal-title":"Eur Neurol"},{"key":"10.1136\/ard.2005.048744_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (Part 1)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1136\/ard.2005.048744_bib15","first-page":"S193","article-title":"Etanercept is effective in the treatment of polymyositis\/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents","volume":"43","author":"Sadeeh","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.048744_bib16","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724200625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724200625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.048744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:18:46Z","timestamp":1737249526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724200625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0003496724200625"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.048744","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.048744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Copyright 2006 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}